G
Gaetano Bacci
Researcher at University of Turin
Publications - 160
Citations - 9583
Gaetano Bacci is an academic researcher from University of Turin. The author has contributed to research in topics: Sarcoma & Osteosarcoma. The author has an hindex of 50, co-authored 159 publications receiving 8971 citations. Previous affiliations of Gaetano Bacci include University of Bologna.
Papers
More filters
Journal ArticleDOI
Primary bone osteosarcoma in the pediatric age: State of the art
TL;DR: The state of the art of treatment for bone osteosarcoma in the pediatric age is reviewed, with the most effective drugs still the same as those employed over the last 20 years as front line neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide.
Journal ArticleDOI
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Stefano Ferrari,Sigbjørn Smeland,Mario Mercuri,Franco Bertoni,Alessandra Longhi,Pietro Ruggieri,Thor Alvegård,Piero Picci,Rodolfo Capanna,Gabriella Bernini,Christoph R. Müller,Amelia Tienghi,Thomas Wiebe,Alessandro Comandone,Tom Böhling,Adalberto Brach del Prever,Otte Brosjö,Gaetano Bacci,Gunnar Sæter +18 more
TL;DR: The addition of high- dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosFamide.
Journal ArticleDOI
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
Nicola Baldini,Katia Scotlandi,G. Barbanti-Brodano,Maria Cristina Manara,Daniela Maurici,Gaetano Bacci,Franco Bertoni,Piero Picci,S. Sottili,Mario Campanacci,Massimo Serra +10 more
TL;DR: In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.
Journal ArticleDOI
Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report
Gaetano Bacci,Stefano Ferrari,Franco Bertoni,Pietro Ruggieri,Piero Picci,Alessandra Longhi,Roberto Casadei,Nicola Fabbri,Cristiana Forni,Michela Versari,Mario Campanacci +10 more
TL;DR: With an aggressive neoadjuvant chemotherapy, it is possible to cure more than 60% of patients with nonmetastatic osteosarcoma of the extremity and amputation may be avoided in more than 80% of them.
Journal ArticleDOI
Prognostic Factors in Nonmetastatic Ewing’s Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli
Gaetano Bacci,Stefano Ferrari,Franco Bertoni,Simonetta Rimondini,Alessandra Longhi,Patrizia Bacchini,Cristiana Forni,Marco Manfrini,Davide Maria Donati,Piero Picci +9 more
TL;DR: The prognosis in cases of nonmetastatic Ewing's sarcoma is influenced by many different clinical and hematologic variables, all of which are to be considered when patients are being stratified according to the risk of relapse.